Marker Therapeutics
MRKR
31 hedge funds and large institutions have $11.9M invested in Marker Therapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
15% more funds holding
Funds holding: 27 → 31 (+4)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.4% less ownership
Funds ownership: 11.73% → 10.34% (-1.4%)
15% less capital invested
Capital invested by funds: $14.1M → $11.9M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.62M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$313K |
| 3 |
Millennium Management
New York
|
+$299K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$118K |
| 5 |
RI
RTW Investments
New York
|
+$83.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.14M |
| 2 |
6CM
683 Capital Management
New York
|
-$859K |
| 3 |
State Street
Boston,
Massachusetts
|
-$191K |
| 4 |
DLHL
Donald L. Hagan LLC
Sarasota,
Florida
|
-$94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$47.2K |
MRKR Hedge Fund Activity: Q3 2018 in Review
31 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2018, worth a combined $11.9M — down 15% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MRKR positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.62M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $3.14M sold.
- 31 institutional investors held Marker Therapeutics (MRKR) as of Q3 2018, up from 27 in Q2 2018.
- Funds reported $11.9M of Marker Therapeutics stock for Q3 2018, down 15% quarter-over-quarter.
- 7 funds opened new Marker Therapeutics positions in Q3 2018 and 3 closed out, a net change of +4 holders.
- The largest Marker Therapeutics buyer in Q3 2018 was Vanguard Group, an estimated $1.62M added.
- The largest Marker Therapeutics seller in Q3 2018 was Driehaus Capital Management, an estimated $3.14M sold.
Based on aggregated 13F filings for Q3 2018.